表紙
市場調查報告書
商品編碼
1084337

全球寵物癌症治療市場趨勢和預測(2022-2028):治療藥物類型、寵物類型、給藥方式、用途和地區

Pet Cancer Therapeutics Market, by Therapy Type, Pet Type, Mode of Administration, Application, and Region - Global Trends, and Forecast, 2022 - 2028

出版日期: | 出版商: Coherent Market Insights | 英文 194 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

寵物抗癌藥市場的增長得益於大量用於治療淋巴瘤、黑色素瘤等常見疾病的在研藥物。私營部門和政府機構共同努力開發犬貓新藥也是預測期內推動市場增長的關鍵因素。另一方面,寵物疾病認知度低、成本高、藥物副作用大是製約市場增長的因素。

本報告調查了全球寵物癌症治療市場,定義和概述了市場,分析了對市場增長、法律和監管環境、管道分析和市場規模變化的各種影響因素。它總結了各個類別的預測、細分/地區/主要國家、競爭環境、主要公司概況等

目錄

第 1 章調查目標/先決條件

第二章市場展望

第三章市場動態/法律法規/趨勢分析

  • 市場動態
    • 促進因素
    • 抑制器
    • 市場機會
  • 主要亮點
  • 管道分析
  • 監管準則
  • 寵物癌症預防倡議
  • 獲批的寵物癌症靶向治療
  • 流行病學

第 4 章全球寵物癌症治療市場:按治療類型

  • 化療
  • 靶向治療
  • 聯合治療
  • 免疫療法

第 5 章全球寵物癌症治療市場:按寵物類型

第 6 章全球寵物癌症治療市場:按管理模式

  • 口語
  • 靜脈注射
  • 本地

第 7 章全球寵物癌症治療市場:按用途

  • 淋巴瘤
  • 肥大細胞癌
  • 黑色素瘤
  • 乳腺癌和鱗狀細胞癌
  • 其他

第 8 章全球寵物癌症治療市場:按地區

  • 北美
  • 拉丁美洲
  • 歐洲
  • 亞太地區
  • 中東
  • 非洲

第9章競爭態勢

  • 熱圖分析
  • 市場份額分析(3x3 矩陣)
  • 公司簡介
    • Aratana Therapeutics, Inc.
    • AB Science
    • Boehringer Ingelheim International GmbH
    • Zenoaq
    • Morphogenesis, Inc.
    • VetDC, Inc.
    • Karyopharm Therapeutics, Inc.
    • Rhizen Pharmaceuticals SA
    • Regeneus Ltd.
    • Oasmia Pharmaceuticals AB
    • Zoetis
  • 分析師觀點

第 10 章 章節

目錄
Product Code: CMI1284

The pet cancer therapeutics include chemotherapy drugs, targeted therapies, combination therapies, and immunotherapy vaccines, which are commonly recommended by the veterinary doctors. The drugs are mostly recommended to treat various conditions such as lymphoma, mast cell tumors, fibrosarcoma, hemangiosarcoma, and others. Currently, a wide range of formulations are available in the global market for the treatment of pet cancers, which can be administered in the form of tablets, injections or can be applied topically. Thus, the large variety of treatment options has made it easy for the pets to receive effective cancer treatment suitable to curb the condition.

Market Dynamics

The major factor driving growth of the pet cancer therapeutics market include robust number of pipeline drugs for the treatment of highly prevalent conditions such as lymphoma and melanoma. For instance, in 2021, Aratana Therapeutics received approval from the United States Department of Agriculture (USDA) Center for Veterinary Biologics for canine osteosarcoma vaccine- AT-014 for the treatment of dogs diagnosed with osteosarcoma, one year of age or older. The drug candidate was licensed exclusively from Advaxis, Inc. and is currently in the pivotal trial. Moreover, the private and government organizations such as Veterinary Cancer Society, Petco Foundation, and Animal Cancer Foundation are working together to formulate novel drugs for dogs and cats, which is a major factor expected to propel growth of the pet cancer therapeutics market over the forecast period. However, lack of awareness regarding pet diseases, high cost, and adverse effects of the drugs are the factors restraining pet cancer therapeutics market growth.

Key features of the study:

This report provides in-depth analysis of pet cancer therapeutics market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by the leading players

It profiles leading players in the global pet cancer therapeutics market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments and strategies, and future plans

Key companies covered as a part of this study include Aratana Therapeutics, Inc., AB Science, Boehringer Ingelheim International GmbH, Zenoaq, Morphogenesis, Inc., VetDC, Inc., Karyopharm Therapeutics, Inc., Rhizen Pharmaceuticals SA, Regeneus Ltd., Oasmia Pharmaceuticals AB, and Zoetis

Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics

The global pet cancer therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the pet cancer therapeutics market

Detailed Segmentation:

Global Pet Cancer Therapeutics Market, By Therapy Type:

Chemotherapy

Targeted Therapy

Combination Therapy

Immunotherapy

Global Pet Cancer Therapeutics Market, By Pet Type:

Cat

Dog

Horse

Global Pet Cancer Therapeutics Market, By Mode of Administration:

Oral

Intravenous

Topical

Global Pet Cancer Therapeutics Market, By Application:

Lymphoma

Mast Cell Cancer

Melanoma

Mammary and Squamous Cell Cancer

Others

Global Pet Cancer Therapeutics Market, By Geography:

North America

By Therapy Type:

Chemotherapy

Targeted Therapy

Combination Therapy

Immunotherapy

By Pet Type:

Cat

Dog

Horse

By Mode of Administration:

Oral

Intravenous

Topical

By Application:

Lymphoma

Mast Cell Cancer

Melanoma

Mammary and Squamous Cell Cancer

Others

By Country:

U.S.

Canada

Latin America

By Therapy Type:

Chemotherapy

Targeted Therapy

Combination Therapy

Immunotherapy

By Pet Type:

Cat

Dog

Horse

By Mode of Administration:

Oral

Intravenous

Topical

By Application:

Lymphoma

Mast Cell Cancer

Melanoma

Mammary and Squamous Cell Cancer

Others

By Country:

Brazil

Mexico

Argentina

Rest of Latin America

Europe

By Therapy Type:

Chemotherapy

Targeted Therapy

Combination Therapy

Immunotherapy

By Pet Type:

Cat

Dog

Horse

By Mode of Administration:

Oral

Intravenous

Topical

By Application:

Lymphoma

Mast Cell Cancer

Melanoma

Mammary and Squamous Cell Cancer

Others

By Country:

Germany

U.K.

France

Italy

Spain

Russia

Rest of Europe

Asia Pacific

By Therapy Type:

Chemotherapy

Targeted Therapy

Combination Therapy

Immunotherapy

By Pet Type:

Cat

Dog

Horse

By Mode of Administration:

Oral

Intravenous

Topical

By Application:

Lymphoma

Mast Cell Cancer

Melanoma

Mammary and Squamous Cell Cancer

Others

By Country:

China

India

Japan

Australia

South Korea

ASEAN

Rest of Asia Pacific

Middle East

By Therapy Type:

Chemotherapy

Targeted Therapy

Combination Therapy

Immunotherapy

By Pet Type:

Cat

Dog

Horse

By Mode of Administration:

Oral

Intravenous

Topical

By Application:

Lymphoma

Mast Cell Cancer

Melanoma

Mammary and Squamous Cell Cancer

Others

By Country:

GCC

Israel

Rest of Middle East

Africa

By Therapy Type:

Chemotherapy

Targeted Therapy

Combination Therapy

Immunotherapy

By Pet Type:

Cat

Dog

Horse

By Mode of Administration:

Oral

Intravenous

Topical

By Application:

Lymphoma

Mast Cell Cancer

Melanoma

Mammary and Squamous Cell Cancer

Others

By Country:

South Africa

Central Africa

North Africa

Company Profiles

Aratana Therapeutics, Inc.*

Company Overview

Product Portfolio

Financial Performance

Key Strategies

Recent Developments

AB Science

Boehringer Ingelheim International GmbH

Zenoaq

Morphogenesis, Inc.

VetDC, Inc.

Karyopharm Therapeutics, Inc.

Rhizen Pharmaceutical SA

Regeneus Ltd.

Oasmia Pharmaceuticals AB

Zoetis

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Therapy Type
    • Market Snippet, By Pet Type
    • Market Snippet, By Mode of Administration
    • Market Snippet, By Application
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Key Highlights
  • Pipeline Analysis
  • Regulatory Guidelines
  • Initiatives for Prevention of Pet Cancer
  • Approved Targeted Therapies for Pet Cancer
  • Epidemiology

4. Global Pet Cancer Therapeutics Market, By Therapy Type, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Chemotherapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Targeted Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Combination Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Immunotherapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

5. Global Pet Cancer Therapeutics Market, By Pet Type, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Cat
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Dog
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Horse
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

6. Global Pet Cancer Therapeutics Market, By Mode of Administration, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Intravenous
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Topical
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

7. Global Pet Cancer Therapeutics Market, By Application, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Lymphoma
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Mast Cell Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Melanoma
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Mammary and Squamous Cell Cancer
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

8. Global Pet Cancer Therapeutics Market, By Region, 2017 - 2028, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017 - 2028
  • North America
    • Market Size and Forecast, By Therapy Type, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Pet Type, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Mode of Administration, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Application, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • U.S.
    • Canada
  • Latin America
    • Market Size and Forecast, By Therapy Type, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Pet Type, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Mode of Administration, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Application, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Therapy Type, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Pet Type, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Mode of Administration, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Application, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Therapy Type, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Pet Type, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Mode of Administration, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Application, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of APAC
  • Middle East
    • Market Size and Forecast, By Therapy Type, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Pet Type, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Mode of Administration, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Application, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Therapy Type, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Pet Type, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Mode of Administration, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Application, 2017 - 2028, (US$ Million)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
    • South Africa
    • Central Africa
    • North Africa

9. Competitive Landscape

  • Heat Map Analysis
  • Market Share Analysis (3x3 Matrix)
  • Company Profiles
    • Aratana Therapeutics, Inc.*
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • AB Science
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Boehringer Ingelheim International GmbH
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Zenoaq
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Morphogenesis, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • VetDC, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Karyopharm Therapeutics, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Rhizen Pharmaceuticals SA
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Regeneus Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Oasmia Pharmaceuticals AB
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
    • Zoetis
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Future Plans
  • Analyst Views

10. Section

  • References
  • Research Methodology
  • About us and Sales Contact